What Challenges Arise When Managing Pharmacovigilance Without Dedicated Safety Software?

A growing biotech's first few adverse event cases usually get tracked the way most early-stage processes get tracked a shared spreadsheet, an email thread with the medical monitor, maybe a shared inbox for incoming reports. At low volume, this works well enough that there's rarely an obvious reason to change it. The problems don't show up at case one or case ten. They show up later, once volume grows, once a regulatory deadline gets missed by a day, or once an auditor asks a question the spreadsheet was never built to answer.

Here are six specific challenges that consistently surface when pharmacovigilance is managed without dedicated safety software.

1. No structured validation against E2B(R3) or regional gateway rules

A spreadsheet doesn't know what a complete, submission-ready case looks like. There's no field-level check confirming a case meets ICH E2B(R3) structural requirements, no flag for a missing narrative element, no automatic validation against EMA EVWEB or FDA ESG rules. Every completeness check depends entirely on someone remembering to look for it.

2. Regulatory deadline tracking relies on memory and manual calendars

Expedited safety reporting timelines are strict, and they start ticking the moment specific criteria are met not when someone gets around to noticing. Without a system that tracks these clocks automatically, deadline management becomes a matter of manual calendar reminders and institutional memory, which is a fragile way to manage a hard regulatory requirement.

3. MedDRA coding has no consistency mechanism

Coding an adverse event to a standard MedDRA term requires either database access and a documented process, or it becomes a matter of individual judgment applied inconsistently case by case. Without a system that pulls terms from the actual hierarchy and checks against prior coding decisions, similar events end up coded differently depending on who handled them.

4. There's no audit trail unless someone builds one manually

21 CFR Part 11 expects an immutable, timestamped record of who did what to a case, and when. A shared spreadsheet or email thread doesn't produce that automatically it requires someone to separately document approvals, changes, and reviews, which is easy to fall behind on exactly when case volume increases.

5. Case quality has no consistent standard

Without a scoring mechanism, some cases get thorough review before submission and others get whatever attention was available that day. There's no way to see, at a glance, which cases in the current queue carry more completeness risk than others — every case gets treated the same regardless of actual readiness.

6. None of it scales past a small number of cases

The tools that work for five cases a month rarely work for fifty. As volume grows, the manual effort required to track, validate, and reconcile cases doesn't grow linearly it grows faster, because more cases mean more places for tracking to fall out of date, more coding inconsistencies, and more deadlines to manually monitor at once.

What generic tools can and can't do

Why this matters under ICH E2B(R3), GVP, and 21 CFR Part 11

Regulatory expectations don't scale down for smaller organizations or lower case volumes. A biotech with five cases a month still needs to meet the same E2B(R3) structural requirements, the same expedited reporting timelines, and the same audit trail expectations as a larger sponsor with a dedicated safety team. Managing that with generic tools doesn't reduce the compliance bar it just means meeting it depends entirely on manual diligence rather than systematic support.

How Cloudbyz's PV tools approach this

Cloudbyz's pharmacovigilance tools are built specifically to close the gaps that generic tools can't address structurally. AI VigiCheck runs real-time E2B(R3) validation and assigns a completeness and quality score to every case before gateway submission, rather than leaving quality assessment to whoever happens to review a given case. The Medical Coding Assistant pulls MedDRA terms directly from the database hierarchy and falls back to historical coding decisions, keeping coding consistent even as case volume and reviewer count grow. E-signature workflows and immutable audit trails are part of the system by default, so the audit trail exists as a byproduct of normal use rather than a separate manual documentation task.

What this means by role

• Founders and Safety leads at growing biotechs get regulatory-grade case handling without needing to build a large dedicated safety team from day one.
• QA and Compliance Directors get a defensible, demonstrable process to present during an inspection, rather than reconstructing case history from email threads.
• Clinical Data Management professionals supporting safety reporting get consistent coding and validation instead of ad hoc judgment calls case by case.

The challenges of managing pharmacovigilance without dedicated software rarely show up at low case volume. They show up later during an audit, at a regulatory deadline, or the first time a case needs to be defended in detail which is exactly when the cost of not having systematic support is highest.

Book a demo with Cloudbyz.